Candriam S.C.A. Sells 105,217 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Candriam S.C.A. decreased its stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 15.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 571,027 shares of the company’s stock after selling 105,217 shares during the period. Candriam S.C.A.’s holdings in Neumora Therapeutics were worth $6,053,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in the stock. Arizona State Retirement System bought a new stake in shares of Neumora Therapeutics in the fourth quarter valued at approximately $172,000. Charles Schwab Investment Management Inc. raised its position in shares of Neumora Therapeutics by 0.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 704,154 shares of the company’s stock valued at $7,464,000 after purchasing an additional 5,899 shares during the period. Windmill Hill Asset Management Ltd raised its position in shares of Neumora Therapeutics by 299.6% in the fourth quarter. Windmill Hill Asset Management Ltd now owns 104,373 shares of the company’s stock valued at $1,106,000 after purchasing an additional 78,252 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Neumora Therapeutics in the fourth quarter valued at approximately $61,000. Finally, SkyOak Wealth LLC raised its position in shares of Neumora Therapeutics by 33.3% in the fourth quarter. SkyOak Wealth LLC now owns 20,000 shares of the company’s stock valued at $212,000 after purchasing an additional 5,000 shares during the period. Institutional investors own 47.65% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on NMRA. Guggenheim cut shares of Neumora Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday. Bank of America reduced their price objective on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating for the company in a research note on Monday, January 6th. Stifel Nicolaus cut shares of Neumora Therapeutics from a “buy” rating to a “hold” rating and reduced their price objective for the company from $6.00 to $2.00 in a research note on Friday. HC Wainwright reduced their price objective on shares of Neumora Therapeutics from $30.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $4.00 price target on shares of Neumora Therapeutics in a research note on Tuesday. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $10.14.

Neumora Therapeutics Price Performance

NASDAQ:NMRA opened at $1.49 on Friday. The firm’s 50-day moving average price is $2.44 and its 200-day moving average price is $8.64. The company has a market capitalization of $240.73 million, a PE ratio of -0.80 and a beta of 2.59. Neumora Therapeutics, Inc. has a 1-year low of $1.30 and a 1-year high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA) last released its earnings results on Thursday, March 6th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.09. Equities analysts anticipate that Neumora Therapeutics, Inc. will post -1.61 EPS for the current fiscal year.

Neumora Therapeutics Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.